The G51S purine nucleoside phosphorylase polymorphism is associated with cognitive decline in Alzheimer's disease patients

Human Psychopharmacology

Volumn 22, Issue 2, 2007, Pages 75-80

  Tumini, Emanuela ^a   Porcellini, Elisa ^a   Chiappelli, Martina ^a   Conti, Chiara M ^b   Beraudi, Alina ^a   Poli, Alessandro ^a   Caciagli, Francesco ^b   Doyle, Robert ^c   Conti, Pio ^b   Licastro, Federico ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Alzheimer's disease; Cognitive decline; G51S polymorphism; Purine nucleoside phosphorylase

Indexed keywords

ADENINE; APOLIPOPROTEIN E4; CHOLINESTERASE INHIBITOR; GLYCINE; GUANINE; PURINE NUCLEOSIDE PHOSPHORYLASE; SERINE;

AGE DISTRIBUTION; AGED; ALLELE; ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; EXON; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PURINE METABOLISM; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; COGNITION DISORDERS; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLYCINE; HUMANS; MUTATION, MISSENSE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PURINE-NUCLEOSIDE PHOSPHORYLASE; RISK FACTORS; SERINE; TIME FACTORS;

EID: 33947718764     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.823     Document Type: Article

References (39)

1. Aust MR, Andrews LG, Barrett MJ, et al. 1992. Molecular analysis of mutations in a patient with purine nucleoside phosphorylase deficiency. Am J Hum Genet 51(4): 763-772.
2. Ballerini P, Ciccarelli R, Caciagli F, et al. 2005 P2X7 receptor activation in rat brain cultured astrocytes increases the biosynthetic release of cysteinyl leukotrienes. Int J Immunopathol Pharmacol 18(3): 17-30.
3. 1 and cysteinyl-leukotriene receptors mediate purine and cysteinyl-leukotriene co-release in primary cultures of rat microglia. Int J Immunopathol Pharmacol 18: 255-268.
4. Bell MJ, Kochanek PM, Carcillo JA, et al. 1998. Interstitial adenosine, inosine, and hypoxanthine are increased after experimental traumatic brain injury in the rat. J Neurotrauma 15(3): 163-170.
5. Burnstock G. 1993. Physiological and pathological role of purines: an update. Drug Develop. Res 28: 195-206.
6. Bzowska A, Kulikowska E, Shugar D. 2000. Purine nucleoside phosphory]ases: properties, functions, and clinical aspects. Pharmacol Ther 88(3): 349-425.
7. Cacabelos R. 2003. The application of functional genomics to Alzheimer's disease. Pharmacogenomics 4(5): 597-621.
8. Ceballos G, Tuttle JB, Rubio R. 1994. Differential distribution of purine metabolizing enzymes between glia and neurons. J Neurochem 62(3): 1144-1153.
9. Chauhan NB, Siegel GJ, Feinstein DL. 2005. Propentofylline attenuates tau hyperphosphorylation in Alzheimer's Swedish mutant model Tg2576. Neuropharmacology 48(1): 93-104.
10. Ciccarelli R, Ballerini P, Sabatino G, et al. 2001. Involvement of astrocytes in purine-mediated reparative processes in the brain. Int J Dev Neurosci 19(4): 395-414.
11. Di Giannantonio M, Frydas S, Kempuraj D, et al. 2005 Cytokines in stress. Int J Immunopathol Pharmacol 18(1): 1-5.
12. Dickson DW, Farlo J, Davies P, et al. 1988. Alzheimer's disease. A double-labeling immuno-histochemical study of senile plaques. Am J Pathol 132(1): 86-101.
13. Domizio S, Barbante E, Puglielli C, et al. 2005. Excessively high magnetic resonance singal in preterm infants and neuropsychobehavioural follow-up at 2 years. Int J Immunopathol Pharmacol 18(2): 365-375.
14. Doody RS, Massman P, Dunn JK. 2001. A method for estimating progression rates in Alzheimer disease. Arch Neurol 58(3): 449-454.
15. Galdiero M, Pisciotta MG, Gorga F, Petrillo G, Marinelli A, Galdiero E. 2005. Modulation of costimulatory molecules CD80/CD86 on B cell and macrophages by stress proteins GroEL, GroES and DnaK. Int J Immunopathol Pharmacol 18(4): 637-644.
16. Gambi F, De Berardis D, Sepede G, et al. 2005. Effect of mirtazapine on thyroid hormones in adult patients with major depression. Int J Immunopathol Pharmacol 18(4): 737-744.
17. Gambi F, De Berardis D, Sepede G, et al. 2005. Cannabinoid receptors and their relationships with neuropsychiatnc disorders. Int J Immunopathol Pharmacol 18(1): 15-19.
18. Giblett ER, Ammann AJ, Wara DW, et al. 1975. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1(7914): 1010-1013.
19. Grundman M, Capparelli E, Kim HT et al. 2003. A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. Life Sci 73(5): 539-553.
20. Haughey NJ, Mattson MP. 2003. Alzheimer's amyloid beta-peptide enhances ATP/gap junction-mediated calcium-wave propagation in astrocytes. Neuromolecular Med 3(3): 173-180.
21. Kittner B, Rossner M, Rother M. 1997. Clinical trials in dementia with propentofyl]ine. Ann N Y Acad Sci 826 307-316.
22. Licastro F, Chiappelli M. 2003. Brain immune responses cognitive decline and dementia: relationship with phenotype expression and genetic background. Mech Ageing Develop 124(4): 539-548.
23. Licastro F, Pedrini S, Govoni M, et al. 1999. Apolipoprotein E and alpha-1-antichymotrypsin allele polymorphism in sporadic and familial Alzheimer's disease. Neurosci Lett 270(3): 129-132.
24. Licastro F, Chiappelli M, Ruscica M, Cameli V, Corsi MM. 2005. Altered cytokine and acute phase response protein levels in the blood of children with Downs syndrome: relationship with dementia of Alzheimer's type. Int J Immunopathol Pharmacol 18: 165-172.
25. Lao DT, Copani A, Pike CJ, et al. 1993. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci USA 90(17): 7951-7955.
26. Mattson MP. 2000. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 1(2): 120-129.
27. McKeith I, Cummings J. 2005. Behavioural changes and psychological symptoms in dementia disorders. Lancet Neurol 4(11): 735-742.
28. Moore D, Iritani S, Chambers J, et al. 2000. Immunohistochemical localization of the P2Y1 purinergic receptor in Alzheimer's disease. Neuroreport 11(17): 3799-3803.
29. Neary JT, Rathbone MP, Cattabeni F, et al. 1996. Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Trends Neurosci 19(1): 13-18.
30. Parvathenani LK, Tertyshnikova S, Greco CR, et al. 2003. P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer's disease. J Biol Chem. 278(15): 13309-13317.
31. Pettifer KM, Kleywegt S, Bau CJ, et al. 2004. Guanosine protects SH-SY5Y cells against beta-amyloid-induced apoptosis. Neureport 15(5): 833-836.
32. Poirier J, Davignon J, Bouthillier D, Kogan S, Bertrand P, Gauthier S. 1993. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 342: 697-699.
33. Rampe D, Wang L, Ringheim GE. 2004. P2X7 receptor modulation of beta-amyloid- and LPS-induced cytokine secretion from human macrophages and microglia. J Neuroimmunol 147(1-2): 56-61.
34. Rogers J, Luber-Narod J, Styren SD, et al. 1988. Expression of immune system-associated antigens by cells of the human central nervous system: relationship to the pathology of Alzheimer's disease. Neurobiol Aging 9(4): 339-349.
35. Sorbi S, Forleo P, Tedde A, et al. 2001. Genetic risk factors in familial Alzheimer's disease. Mech Ageing Dev 122(16): 1951-1960.
36. Strittmatter WJ, Roses AD. 1996. Apolipoprotein E and Alzheimer's disease. Annu Rev Neurosci 19: 53-77.
37. Terry RD. 1994. Neuropathological changes in Alzhemier disease. Prog Brain Res 101: 383-390.
38. Totaro R, Passacantando A, Russo T, et al. 2005. Effects of interferon beta, cyclophosphamide, and azathioprine on cytokine profile in patients with multiple sclerosis. Int J Immunopathol Pharmacol 18: 377-384.
39. Tuppo EE, Arias HR. 2005. The role of inflammation in A]zheimer's disease. Int J Biochem Cell Biol. 37(2): 289-305.